Evidence map›Paper›PMID 42146233›Full record

ArticleACS omega2026

Biofabricated Alginate Hydrogels to Study Prostate Tumoral Microenvironments In Vitro.

Khalsa Al-Husaini, Eugenia Spessot, Esther Baena, Marco Domingos, Annalisa Tirella

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Khalsa Al-HusainiDivision of Pharmacy and Optometry, Medicine and Health, The University of Manchester, M13 9PL Manchester, U.K.
Eugenia SpessotDepartment of Industrial Engineering, Biotech Center for Biomedical Technologies, University of Trento, 38122 Trento, Italy.ORCID https://orcid.org/0000-0002-8367-7847
Esther BaenaCancer Research UK Manchester Institute, The University of Manchester, M13 9PL Manchester, U.K.
Marco DomingosDepartment of Mechanical and Aerospace Engineering, School of Engineering, Faculty of Science and Engineering & Henry Royce Institute, The University of Manchester, M13 9PL Manchester, U.K.ORCID https://orcid.org/0000-0002-6693-790X
Annalisa TirellaDivision of Pharmacy and Optometry, Medicine and Health, The University of Manchester, M13 9PL Manchester, U.K.ORCID https://orcid.org/0000-0002-3743-3593

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Engineered three-dimensional (3D) in vitro models are essential for recapitulating the human tumor microenvironment (TME) and deciphering the complex cell-material interactions driving cancer progression. This study presents the development of a prostate-specific bioprinted model designed to mimic both the biomechanical (stiffness) and biochemical (laminin-enriched) traits of the prostate cancer (PCa) extracellular matrix (ECM). We synthesized functionalized alginate hydrogels modified with laminin-mimetic peptides (IKVAV, AG73) and tuned their mechanical properties (2-20 kPa) to match the transition from healthy tissue to advanced/metastatic disease. Functionalized alginate hydrogel precursors were compatible with extrusion-based bioprinting and used to replicate TME heterogeneity by 3D bioprinting in vitro models containing PC-3 cells and cancer-associated fibroblasts (CAFs). PC-3 cells cocultured with cancer-associated fibroblasts (CAFs) within these hydrogels supported high cell viability and proliferation. Notably, phenotypic analysis revealed that stiffer, laminin-enriched matrices significantly upregulated the expression of CD44 and the epithelial-to-mesenchymal transition (EMT) marker vimentin in PC-3 cells. Interestingly, these matrix-driven effects were dominant, independent of the CAF presence within the observed window. This work establishes a robust, scalable biofabrication strategy for generating TME-mimetic models, offering a valuable tool for future studies in screening TME-targeting therapies and investigating the mechanobiology of PCa progression.

Identifiers

PMID42146233
PMCPMC13176988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.